Combining comprehensive bioinformatics analysis and in vitro and in vivo experiments, we are the first to report that SH3TC2 is a novel oncogene and may act as a potential prognostic biomarker and therapeutic target for CRC. This evidence concerns the gene SH3TC2 and colorectal carcinoma.